Lee Chul Ho, Cho Jun Woo, Jang Jae Seok, Yoon Tae Hong
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Catholic University of Daegu, Daegu, Korea.
Korean J Thorac Cardiovasc Surg. 2020 Apr 5;53(2):58-63. doi: 10.5090/kjtcs.2020.53.2.58.
Despite progress in treatment, Stanford type A aortic dissection is still a life-threatening disease. In this study, we analyzed surgical outcomes in patients with Stanford type A aortic dissection according to the extent of surgery at Daegu Catholic University Medical Center.
We retrospectively analyzed 98 patients with Stanford type A aortic dissection who underwent surgery at our institution between January 2008 and June 2018. Of these patients, 82 underwent limited replacement (hemi-arch or ascending aortic replacement), while 16 patients underwent total arch replacement (TAR). We analyzed in-hospital mortality, postoperative complications, the overall 5-year survival rate, and the 5-year aortic event-free survival rate.
The median follow-up time was 48 months (range, 1-128 months), with a completion rate of 85.7% (n=84). The overall in-hospital mortality rate was 8.2%: 6.1% in the limited replacement group and 18.8% in the TAR group (p=0.120). The overall 5-year survival rate was 78.8% in the limited replacement group and 81.3% in the TAR group (p=0.78). The overall 5-year aortic event-free survival rate was 85.3% in the limited replacement group and 88.9% in the TAR group (p=0.46).
The extent of surgery was not related to the rates of in-hospital mortality, complications, aortic events, or survival. Although this study was conducted at a small-volume center, the in-hospital mortality and 5-year survival rates were satisfactory.
尽管在治疗方面取得了进展,但 Stanford A 型主动脉夹层仍然是一种危及生命的疾病。在本研究中,我们根据大邱天主教大学医学中心的手术范围分析了 Stanford A 型主动脉夹层患者的手术结果。
我们回顾性分析了 2008 年 1 月至 2018 年 6 月在我院接受手术的 98 例 Stanford A 型主动脉夹层患者。其中,82 例接受了有限置换(半弓或升主动脉置换),而 16 例患者接受了全弓置换(TAR)。我们分析了住院死亡率、术后并发症、总体 5 年生存率和 5 年无主动脉事件生存率。
中位随访时间为 48 个月(范围 1 - 128 个月),完成率为 85.7%(n = 84)。总体住院死亡率为 8.2%:有限置换组为 6.1%,TAR 组为 18.8%(p = 0.120)。有限置换组的总体 5 年生存率为 78.8%,TAR 组为 81.3%(p = 0.78)。有限置换组的总体 5 年无主动脉事件生存率为 85.3%,TAR 组为 88.9%(p = 0.46)。
手术范围与住院死亡率、并发症、主动脉事件或生存率无关。尽管本研究是在一个小容量中心进行的,但住院死亡率和 5 年生存率令人满意。